MedDRA Coding and Versioning

Similar documents
Advanced MedDRA Coding

Coding with MedDRA 4/22/2015

Coding with MedDRA 3/2/2017

Coding with MedDRA 3/6/2019

Introduction to MedDRA

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA - International standard for coding safety information. The Golden Triangle

Coding with MedDRA 1

MedDRA Basic Concept

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

MedDRA Coding Quality: How to Avoid Common Pitfalls

Coding with MedDRA 1

What Medical Writers Need to Know About MedDRA

Safety Data Analysis and Query Creation with MedDRA

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Coding with Confidence

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Use of MedDRA in Special Situations

Data retrieval using the new SMQ Medication Errors

Coding with MedDRA. Course Overview

MedDRA Overview A Standardized Terminology

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

MedDRA TERM SELECTION: POINTS TO CONSIDER

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

What s New MedDRA Version March

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

What s New MedDRA Version March

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

What s New MedDRA Version MSSO-DI March 2016

Product Information BROWN SNAKE ANTIVENOM AUST R 74897

Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

What s New MedDRA Version 18.0

Search for studies: ClinicalTrials.gov Identifier: NCT

APR-DRG Description Ave Charge

Part VI: Summary of the risk management plan by product

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell

belimumab (rmc) 120 mg and 400 mg powder Please read this leaflet carefully before you are given BENLYSTA.

What s New MedDRA Version 13.1

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

Frequently Asked Questions

MedDRA Safety Data Analysis and SMQs

Safety Assessment in Clinical Trials and Beyond

CSS Perspective - Opioid Risk Management

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Perspective: E2B transmission

Isle of Wight Joint Strategic Needs Assessment: Core Dataset 2009

PHARMACOVIGILANCE GLOSSARY

A Review of FDA PRO Labeling ( ) Ari Gnanasakthy RTI Health Solutions

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

MedDRA: Safety Data Analysis and SMQs

Present-on-Admission (POA) Coding

MedDRA: Safety Data Analysis and SMQs

Prioritized ShortList MORBIDITY

Episodes of Care Risk Adjustment

Pharmacovigilance Methods and Post-Authorisation Safety Studies

Database of Adverse Event Notifications - medicines

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Serious Adverse Event (SAE) Form Clinical Trials

April 10, 2008 VIA ELECTRONIC MAIL

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

Contrast Materials Patient Safety: What are contrast materials and how do they work?

PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis

Diagnosis-specific morbidity - European shortlist

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

Billing and Coding Information

Immodium / loprarmide

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]

ICD 10 CM Coding and Documentation

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

Fever and Antipyretic Use in Children Janice E. Sullivan, M.D. Professor of Pediatrics University of Louisville

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Observational Medical Outcomes Partnership

Package Leaflet: Information for the user. MAGNEVIST 2 mmol/l solution for injection dimeglumine gadopentetate

Internal Medicine Certification Examination Blueprint

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

PACKAGE LEAFLET: INFORMATION FOR THE USER. Echinaforce Cold & Flu oral drops Echinacea purpurea herb & root tinctures

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

Guidance on Unanticipated Problems (UPs) and Adverse Events (AEs) Bertha delanda IRB Training Specialist Research Compliance Office March 2010

NCCP Chemotherapy Protocol. Afatinib Monotherapy

Package leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin

All medical disabilities are similar in that they are caused

NEW PATIENT FORM. Please print in ink and fill in all blanks Please fill out front and back. Patient s Full Name

Transcription:

MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org

Agenda ICH MedDRA coding guide Coding errors identified by FDA Factors impact coding quality MSSO Versioning for Clinical Trial Best Practice Document ICH MedDRA versioning guide Versioning timing Versioning methodologies MedDRA coding quiz 2

ICH MedDRA Coding Guide

MedDRA Term Selection: PTC Synchronized with MedDRA Version Available on MedDRA.org website Promote accurate and consistent coding 4

Use Current LLTs Lowest Level Term that most accurately reflects the reported verbatim information should be selected Degree of specificity may be challenging Example: Abscess on face select Facial abscess not simply Abscess Select current LLTs only Non-current terms for legacy conversion/historical purposes 5

Do Not Add Information Do not make diagnosis if only signs/symptoms reported Reported LLT Selected Comment Abdominal pain Abdominal pain, increased serum amylase, and increased serum lipase Serum amylase increased Lipase increased It is inappropriate to assign an LLT for diagnosis of pancreatitis 6

Do Not Alter MedDRA MedDRA is a standardized terminology with a pre-defined term hierarchy Users must not make ad hoc structural alterations, including changing the primary SOC allocation If terms are incorrectly placed, submit a change request to the MSSO 7

Term Selection Points Diagnoses and Provisional Diagnoses with or without Signs and Symptoms Death and Other Patient Outcomes Suicide and Self-Harm Conflicting/Ambiguous/Vague Information Combination Terms Age vs. Event Specificity Body Site vs. Event Specificity Location-Specific vs. Microorganism-Specific Information Modification of Pre-existing Conditions Exposures During Pregnancy and Breast Feeding Congenital Terms Neoplasms Medical and Surgical Procedures Investigations 8

Term Selection Points (cont) Medication Errors, Accidental Exposures and Occupational Exposures Misuse, Abuse and Addiction Transmission of Infectious Agent via Product Overdose, Toxicity and Poisoning Device-related Terms Drug Interactions No Adverse Effect and Normal Terms Unexpected Therapeutic Effect Modification of Effect Social Circumstances Medical and Social History Indication for Product Use Off Label Use Product Quality Issues 9

Diagnoses and Provisional Diagnoses SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis without signs and symptoms Diagnosis (only possible option) Example: Myocardial infarction select Myocardial infarction PROVISIONAL DIAGNOSIS Single provisional diagnosis without signs and symptoms Provisional diagnosis (only possible option) Example: Possible myocardial infarction select Myocardial infarction (select term as if definitive diagnosis) Similar principles apply for multiple diagnoses 10

Diagnoses and Provisional Diagnoses (cont) SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis with signs/ symptoms PROVISIONAL DIAGNOSIS Single provisional diagnosis with signs/symptoms Preferred: Diagnosis only Preferred: Provisional diagnosis and signs/symptoms Example: Anaphylactic reaction with rash, dyspnoea, hypotension, and laryngospasm select Anaphylactic reaction Example: Possible myocardial infarction with chest pain, dyspnoea, diaphoresis select Myocardial infarction Chest pain, Dyspnoea, and Diaphoresis Similar principles apply for multiple diagnoses 11

Diagnoses and Provisional Diagnoses (cont) SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis with signs/ symptoms PROVISIONAL DIAGNOSIS Single provisional diagnosis with signs/symptoms Alternate: Diagnosis and signs/symptoms Alternate: Signs/symptoms only (as provisional diagnosis may change Example: Anaphylactic reaction Example: Possible myocardial with rash, dyspnoea, hypotension, infarction with chest pain, and laryngospasm select dyspnoea, diaphoresis select Anaphylactic reaction, Rash, Chest pain, Dyspnoea, and Dyspnoea, Hypotension, and Diaphoresis Laryngospasm Similar principles apply for multiple diagnoses 12

Coding Errors Identified By FDA

Soft Coding Selecting a term which is both less specific and less severe than another MedDRA term is soft coding Example: Liver failure coded as hepatotoxicity or increased LFTs Example: Aplastic anemia coded as unspecified anemia Example: Rash subsequently diagnosed as Stevens Johnson syndrome coded as rash Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance and Epidemiology, CDER

Missed Concepts All medical concepts described after the product is taken should be coded Example: The patient took drug X and developed alopecia, increased LFTs and pancreatitis. Manufacturer only codes alopecia and increased LFTs (missed concept of pancreatitis) Example: The patient took drug X and developed interstitial nephritis which later deteriorated into renal failure. Manufacturer only codes interstitial nephritis (missed renal failure concept) Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance and Epidemiology, CDER

Inappropriate Lumping Not so Bad Not so bad Bad.. Not so bad Original terms. Lumped Terms Acknowledgement: Dr. Christopher Breder, Office of New Drug, CDER Disclaimer: The views expressed represent my opinions and do not necessarily represent the views of the FDA

laryngospasm Inappropriate Lumping Example OR + urticaria angioedema Drug allergy 17

Inappropriate Splitting AE1 Syndrome AE2 AE3 Acknowledgement: Dr. Christopher Breder, Office of New Drug, CDER Disclaimer: The views expressed represent my opinions and do not necessarily represent the views of the FDA

Inappropriate Splitting Example Mouth ulceration Lupus Arthritis Nephritis Fever 19

Event Dilution Procedural Hypotension Hypo-tension Hypo tension SOC Injury, Poison, Proc. Compx. SOC Vascular Disorders Acknowledgement: Dr. Christopher Breder, Office of New Drug, CDER Disclaimer: The views expressed represent my opinions and do not necessarily represent the views of the FDA

Factors Impact Coding Quality

Loss of brain? Quality of Source Data Abdominal discomfort secondary to airplane food ingestion Dependence symptom on pachinko pinball machine 22

Coding Conventions ICH Coding Guide Company specific coding convention Without conventions With conventions 23

Training Training on MedDRA Training on ICH Coding Guide Training on company coding guide Training on company tools used in coding, such as a MedDRA Browser Training on the job by experience colleagues 24

QC/QA Opportunity to identify coding errors and bias and deviation from the coding convention QC scope: manually coded terms and autoencoded terms Autoencoder pitfalls Allergic to CAT scan autoencoded as: LLT Allergic to cats 25

Communication Communicate coding issues with the coding team Between QC/QA staff and coding staff Between sponsor and CRO Establish corrective and preventive actions Follow up on results 26

MSSO Versioning for Clinical Trial Best Practice Document

MedDRA Implementation and Versioning for CTs Available on MedDRA.org website 28

MedDRA Implementation and Versioning for CTs (cont.) Six options with Option 6 being the commonly adopted practice Option 6: Re-code the trial data for all trials in a project on an ongoing basis with the most recent version of MedDRA Trial 1 Trial 2 Trial 3 2010 2011 2012 2013 2014 29

ICH MedDRA Versioning Guide

MedDRA Versioning PTC Document Section 4 of MedDRA Term Selection: PTC Document Timing of version implementation 31

MedDRA Versioning PTC Document (cont.) Versioning methodologies 32

MedDRA Coding Quiz

Which LLT Would you Select? Verbatim: She had a pathologic fracture of the neck of the left femur A. Femoral neck fracture B. Pathologic fracture of neck of femur C. Fracture of neck of femur D. Femur fracture 34

Which LLT Would you Select? Verbatim: Hypernatraemia (Serum sodium = 115 meq/l) A. Serum sodium abnormal B. Hypernatraemia C. Hyponatraemia D. Serum sodium decreased 35

Questions?